In 2006, Shinya Yamanaka and Kazutoshi Takahashi reported their landmark discovery of induced pluripotent stem cells (iPSCs) in Cell. Their demonstration that pluripotent stem cells could be generated by expressing a cocktail of four defined factors in mouse fibroblasts transformed our view of cell fate and its reversibility. At the time, we were excited to be publishing a paper that posed new possibilities for unlocking and shaping cell fate, and upon publication we quickly learned that it would inspire and stimulate urgent new research questions for the field. Would the technology be applicable to human cells? Would iPSCs offer a viable alternative to embryonic stem cells and the accompanying ethical quandaries? How would they change the concept of personalized medicine? In the 10 years that have transpired, the impact has proven immense. IPSC technology has added fundamental insights to our understanding of cell fate regulation, mammalian development, and human disease, and the clinical outlook for cell therapy and drug discovery are perhaps even more exciting, with the first patient receiving experimental treatment in a clinical trial in Japan. At Cell Press, we are celebrating the tenth anniversary of the iPSC discovery with a year-long series of reviews covering key achievements over the past decade and new applications in cell biology and regenerative medicine.
Editors Debbie Sweet of Cell Stem Cell and Elena Porro of Cell recall a sense of intrigue and anticipation upon first hearing Shinya Yamanaka present the work and later when he submitted it for consideration at Cell (they discuss the discovery in a PaperClip interview available with this Editorial online). The impact of the work on publication was immediate and electric, due in part to the profound robustness and reproducibility of the original protocol. The paper remains one of the most read scientific studies of the new millennium. Having opened up stem cell research to new investigators and new questions, growth in the field dramatically accelerated. In tandem, Cell Press has deepened its engagement with the community as it has grown, most notably with the launch of Cell Stem Cell in 2007 and Stem Cell Reports in 2013, both created in partnership with the International Society for Stem Cell Research.
In the year following, Yamanaka and colleagues (along with James Thomson and colleagues publishing in Science) achieved success in inducing pluripotency in human cells, and a suite of papers further bolstered the proof of pluripotency by generating chimeras using mouse iPSCs. These wave-making discoveries helped to kick off a discussion of the potential applications for iPSCs in personalized medicine and the relative merits of iPSCs versus embryonic stem cells-a discussion that continues to this day. A chronicle of the major scientific achievements that followed is presented in a Timeline on page 580 of this issue. Induced pluripotency soon expanded beyond fibroblasts to other types of terminally differentiated cells, and new factors capable of promoting pluripotency, including small molecules, were discovered. Further applications of iPSCs have been rapidly imagined and realized, including their use for modeling disease and drug screening. The innovations have progressed in ways that could not have been predicted back in 2006, with discoveries from iPSCs synergizing with many other fields and technologies, including advances in genomics, epigenomics, and genome editing. The resounding impact of iPSCs, along with previous foundational work on nuclear reprogramming, was recognized when Shinya Yamanaka and John Gurdon received the Nobel Prize for Physiology and Medicine in 2012.
As we enter the second decade of iPSC research, we are taking an opportunity to focus a critical eye at how the field has progressed and the outlook for the challenges ahead. Throughout 2016, Cell and Cell Stem Cell will present a series of reviews (easily identified by the logo atop this Editorial) covering all things iPSC-from fundamental questions the technology can address to debates about the ethics and regulation of clinical translation and new applications in regenerative medicine. These pieces will also be archived at a dedicated website at www.cell.com/iPSC. We view the level of enthusiasm and debate in the field as one of its most exciting aspects, and we will build on that throughout the year online via social media (posted with #IPSC10year) and with our 10 years of iPSCs Cell Symposium in Berkeley this Fall (www.cell-symposia-ipscs.com). Our goal is to foster critical discussion and debate within the field as it steps into this next phase of development.
10 years from now, what might we say about the impact of iPSCs? iPSCs will no doubt provide the lens through which we'll come to understand the richness and flexibility of cellular identity. And we'll gain new insights about the complexity and diversity of human disease as the global community continues to amass human iPSC lines in cell banks for research and therapy. What is more unknowable, however, is the impact in medicine of transplanted iPSC-derived cells. While the potential uses appear nearly without limit, the challenge in particular of integrating derived cells into diseased or damaged tissues remains daunting. We are now only beginning to scratch the surface of how iPSCs may be engineered to form complex tissues with recent advances in organoid technology. In the coming decade, Cell Press will be excited to witness and promote the unleashing of this potential in cellular medicine, just as the discovery 10 years ago unleashed new possibilities for the cell. 
